PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Immune

Thymosin alpha-1

Also written as: Thymalfasin, Zadaxin (brand name of a licensed product sold outside the US), Thymosin alpha 1, Thymosin α1, Tα1, Ta1, Thymosin alpha-1 acetate (a salt form)

Known for
Talked about as an immune booster that helps the body fight infections.
What studies show
In the largest trial, 1,106 adults with sepsis, deaths at 28 days were 23.4% with thymosin alpha-1 and 24.1% with placebo; no trial in healthy people for immune support was found.

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid immune peptide that is licensed as a medicine in some countries but not in the United States; it has been tested in many human trials, and the largest and best-designed ones did not show a clear benefit.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • Thymosin alpha-1 is a 28-amino-acid peptide first isolated from calf thymus in 1977. The man-made version is called thymalfasin.
  • It is not approved by the FDA. It is licensed in some other countries, for example in Italy as an add-on to flu vaccination in people with weak immune systems.
  • The largest trial, in 1,106 adults with sepsis in China, found no reduction in deaths at 28 days (23.4% with thymosin alpha-1, 24.1% with placebo).
  • In hepatitis, the FDA's 2024 review found that the only double-blind hepatitis B trial did not confirm a benefit, and a 552-patient hepatitis C trial found no overall difference in cure rates.
  • In trials, side effects were mostly mild reactions where the injection was given. The FDA's stated concern is about immune reactions and impurities in pharmacy-made versions.
  • It is not on the list US pharmacies may compound from. FDA advisers voted 17 to 4 against adding it in December 2024.
  • It is not named on the 2026 or 2027 World Anti-Doping Agency list, and its approval in Italy and other countries keeps it outside the class for unapproved substances (S0).

What it is

Thymosin alpha-1 is a small peptide (a short chain of amino acids, the building blocks of proteins). It is 28 amino acids long and carries a small chemical cap, called an acetyl group, on its front end. The US Food and Drug Administration (FDA) describes it as naturally present in the human body. The version used in medicine is made in a factory by chemical synthesis and is called thymalfasin. It has the same amino acid sequence as the natural peptide.

More on what it is and where it came from

Unlike most peptides discussed on this site, thymosin alpha-1 is a licensed medicine in some countries. A finished product called Zadaxin is sold outside the United States. In Italy, for example, it is authorised as an add-on to flu vaccination in people with weakened immune systems. It is not approved in the United States for any use. FDA has stated that it has approved no drug product containing thymosin alpha-1.

It has been studied in people for more than 40 years, in hepatitis B and C, sepsis (a life-threatening reaction to infection), COVID-19, cancer and as a vaccine helper. The results are mixed. Several small or unblinded studies looked promising. The larger and more carefully controlled trials mostly did not confirm a benefit. When FDA reviewed the evidence in 2024 for 12 proposed uses, it concluded that evidence of effectiveness was lacking for all of them.

In 1977 Allan Goldstein and colleagues reported that they had isolated thymosin alpha-1 from calf thymus (the thymus is a gland behind the breastbone where immune cells called T cells mature) and worked out its sequence. It was one of several peptides found in a crude thymus extract called thymosin fraction 5. In 1979 Low and Goldstein reported that a synthetic copy was as active as the natural peptide in their laboratory tests. According to FDA's 2024 review, the US National Cancer Institute began early clinical trials at five institutions from 1980. The synthetic peptide was later sold under the brand name Zadaxin by SciClone Pharmaceuticals, mainly in China.

How it is thought to work

Thymosin alpha-1 is described as an immunomodulator, meaning a substance that changes how the immune system behaves. FDA's 2024 review summarised laboratory and animal reports that it can raise the activity of natural killer cells, push helper T cells toward a pattern suited to fighting viruses and other invaders inside cells, raise numbers of killer T cells, and activate dendritic cells (cells that show pieces of germs to the rest of the immune system).

More on how it works

One proposed route is through toll-like receptors, which are sensors that immune cells use to detect infection. In a 2004 study, thymosin alpha-1 made dendritic cells mature and release a signalling protein through these sensors, and it protected mice that had received transplants from a fungal infection. A 2006 study from the same group reported that it can also switch on a braking pathway that promotes regulatory T cells, which calm immune responses. So it may both stimulate and restrain immunity, depending on the setting.

How much of this matters in people is not settled. FDA noted that most animal studies used amounts far higher, relative to body size, than those used in human trials, which makes the lab findings hard to translate. In human trials, thymosin alpha-1 has shifted some blood immune markers, but in the largest trial that did not translate into fewer deaths.

What is established in people

Thymosin alpha-1 has been tested in thousands of patients, which sets it apart from most research peptides. What is established is that it was generally well tolerated in trials and can shift some blood markers of immune function. What is not established is that it improves outcomes that matter to patients. The largest trial (1,106 adults with sepsis) found no reduction in deaths, and a 2025 pooled analysis of 11 sepsis trials found fewer deaths overall but no significant benefit when only the high-quality trials were counted. The only double-blind placebo-controlled hepatitis B trial was negative, and a 2026 Cochrane review of 10 hepatitis B trials found it may reduce deaths but rated that evidence very low certainty, its authors saying they are not sure it has any effect. A 552-patient hepatitis C trial found no overall difference in cure rates, and the COVID-19 evidence is mixed and mostly not randomised. No trial was found that tested it in healthy people for general immune support.

What the studies found

14 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2026

    Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance.

    Adding thymosin alpha-1 significantly increased survival without a liver transplant at 90 days, according to the abstract, which does not give the percentages.

    Full finding, who was studied, and limits

    Who: An open-label randomised trial (NCT03082885) in 73 patients in China with acute-on-chronic liver failure caused by hepatitis B (a sudden, life-threatening worsening of long-term liver disease): 38 received standard treatment and 35 received standard treatment plus thymosin alpha-1. Third Affiliated Hospital of Sun Yat-sen University, Guangzhou.

    Adding thymosin alpha-1 significantly increased survival without a liver transplant at 90 days, according to the abstract, which does not give the percentages. It was associated with fewer regulatory T cells (immune cells that dampen responses) at weeks 4 to 8 and a smaller late surge of inflammation, without blunting early immune activation.

    Read with care: Small, open-label (patients and doctors knew who got the drug) and from one centre. The abstract does not give the survival figures, and this paper focuses on immune mechanisms; the survival result may have been reported earlier from the same trial. Not tested in healthy people.

    Immunopharmacology and Immunotoxicology · pubmed.ncbi.nlm.nih.gov

  2. Human trial2025

    The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.

    Death from any cause within 28 days occurred in 127 patients (23.4%) on thymosin alpha-1 and 132 (24.1%) on placebo, with no significant difference.

    Full finding, who was studied, and limits

    Who: 1,106 adults aged 18 to 85 with sepsis at 22 centres in China, enrolled September 2016 to December 2020: 552 were assigned to thymosin alpha-1 and 554 to placebo, given for 7 days. 1,089 were included in the main analysis (542 and 547). This is the largest trial of thymosin alpha-1 found.

    Death from any cause within 28 days occurred in 127 patients (23.4%) on thymosin alpha-1 and 132 (24.1%) on placebo, with no significant difference. Deaths at 90 days were also similar (31.0% versus 32.4%). No secondary or safety outcome differed significantly. In planned subgroup analyses, patients aged 60 or over leaned toward benefit and patients under 60 did worse with the drug; patients with diabetes also leaned toward benefit. The authors concluded there was 'no clear evidence' that thymosin alpha-1 reduces 28-day deaths in adults with sepsis.

    Read with care: Well designed and large, and the main result was null. The subgroup patterns are leads for future research, not proof, and the under-60 result points toward possible harm. All patients were in China. Funders included SciClone Pharmaceuticals, the maker of Zadaxin. The published hazard ratio differs slightly between copies of the paper (see note); either way the confidence range comfortably includes no effect.

    The BMJ (ClinicalTrials.gov NCT02867267) · pubmed.ncbi.nlm.nih.gov

  3. Human trial2023

    A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.

    Recovery was not significantly faster with thymalfasin, in patients on low-flow oxygen or on high-flow oxygen.

    Full finding, who was studied, and limits

    Who: 49 adults in hospital in the United States with COVID-19, low blood oxygen and low white blood cell counts: 23 received thymalfasin for 7 days on top of standard care and 26 received standard care alone. Not blinded.

    Recovery was not significantly faster with thymalfasin, in patients on low-flow oxygen or on high-flow oxygen. FDA's review of the full paper found no differences in deaths at 28 days or in the need for a ventilator. In the low-flow group, counts of one type of T cell rose faster with treatment (P = 0.01). Nine serious adverse events occurred in treated patients; all were judged unrelated to the drug.

    Read with care: Small and unblinded. The only positive finding was a blood cell count in a subgroup, not a clinical outcome. Funded by SciClone Pharmaceuticals. FDA describes it as one of only two randomised COVID-19 trials and the only one completed in the United States.

    The Journal of Infectious Diseases (ClinicalTrials.gov NCT04487444) · pubmed.ncbi.nlm.nih.gov

  4. Human trial2013

    The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial.

    Deaths within 28 days were 26.0% with thymosin alpha-1 and 35.0% in the control group.

    Full finding, who was studied, and limits

    Who: 361 intensive care patients with severe sepsis at six teaching hospitals in China, enrolled 2008 to 2010: 181 received thymosin alpha-1 for 7 days on top of usual care and 180 received salt-water injections.

    Deaths within 28 days were 26.0% with thymosin alpha-1 and 35.0% in the control group. One statistical test gave P = 0.062 (not significant) and another gave P = 0.049 (just significant). The relative risk of death was 0.74, with a range from 0.54 to 1.02. A blood marker of immune function improved more in the treated group. No serious side effect was attributed to the drug.

    Read with care: Only patients were blinded, because no identical-looking placebo was available. The result sat on the edge of statistical significance, and the effect was smaller than the trial was designed to detect. The authors said larger trials were needed. The larger trial that followed (TESTS, next entry) did not confirm the benefit.

    Critical Care · pubmed.ncbi.nlm.nih.gov

  5. Human trial2012

    Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?

    Cure rates (virus still undetectable after treatment ended) were 12.7% with thymosin alpha-1 and 10.5% with placebo, not a significant difference (P = 0.407).

    Full finding, who was studied, and limits

    Who: 552 patients with chronic hepatitis C who had not responded to earlier treatment: 275 received thymosin alpha-1 and 277 received placebo, both on top of standard interferon-based treatment, for 48 weeks.

    Cure rates (virus still undetectable after treatment ended) were 12.7% with thymosin alpha-1 and 10.5% with placebo, not a significant difference (P = 0.407). Among only the patients who finished all 48 weeks, the rates were 41.0% versus 26.3% (P = 0.048). The authors concluded that thymosin alpha-1 did not improve the response during treatment and had no primary role, and suggested it might help prevent relapse. Side effects did not differ between groups.

    Read with care: The main analysis was negative. The favourable result comes from a subset of patients who completed treatment, which is weaker evidence. The background treatment used is now outdated.

    Journal of Viral Hepatitis · pubmed.ncbi.nlm.nih.gov

  6. Human trial2010

    Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.

    Tumours shrank in 10 and 12 patients in two of the thymosin alpha-1 groups, compared with 4 in the control group.

    Full finding, who was studied, and limits

    Who: 488 patients with advanced (stage IV) melanoma, randomised to one of five groups: chemotherapy with thymosin alpha-1 at different strengths, with or without interferon, or chemotherapy plus interferon alone (the control). Not blinded.

    Tumours shrank in 10 and 12 patients in two of the thymosin alpha-1 groups, compared with 4 in the control group. Median survival was 9.4 months with thymosin alpha-1 versus 6.6 months in the control group, a difference that was not statistically significant (P = 0.08). Adding thymosin alpha-1 did not add toxicity.

    Read with care: FDA's reading of the full paper is that response rates did not differ significantly between any of the groups, and that neither survival nor time without the cancer growing was significantly better. The trial was exploratory, and the comparison treatments are rarely used now. Modern melanoma drugs have since shown much larger benefits.

    Journal of Clinical Oncology · pubmed.ncbi.nlm.nih.gov

  7. Human trial1999

    Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.

    A complete response (virus and viral marker cleared from the blood) occurred in 7 patients (14%) on thymosin alpha-1 and 2 (4%) on placebo.

    Full finding, who was studied, and limits

    Who: 97 patients with chronic hepatitis B at several centres: 49 received thymosin alpha-1 and 48 received placebo for 6 months, with 6 more months of follow-up.

    A complete response (virus and viral marker cleared from the blood) occurred in 7 patients (14%) on thymosin alpha-1 and 2 (4%) on placebo. The difference was not statistically significant (P = 0.084). The authors wrote that the results 'do not confirm observations of treatment efficacy reported in other clinical studies.'

    Read with care: This is the negative result. FDA's 2024 review calls it the only double-blind study comparing thymosin alpha-1 alone with placebo in hepatitis B, and says it failed to demonstrate efficacy. It was small, so a modest benefit cannot be ruled out. A separate trial in 316 Japanese patients compared two strengths with each other but had no placebo group.

    Journal of Viral Hepatitis · pubmed.ncbi.nlm.nih.gov

  8. Human trial1998

    Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial.

    At 18 months, the virus and a key viral marker had cleared from the blood in 40.6% of the 26-week group, 26.5% of the 52-week group and 9.4% of the untreated group.

    Full finding, who was studied, and limits

    Who: 98 patients with chronic hepatitis B, randomised to thymosin alpha-1 for 26 weeks (32 patients), thymosin alpha-1 for 52 weeks (34), or no treatment (32), all followed for 18 months.

    At 18 months, the virus and a key viral marker had cleared from the blood in 40.6% of the 26-week group, 26.5% of the 52-week group and 9.4% of the untreated group. The 26-week group differed significantly from untreated (P = 0.004); the 52-week group did not (P = 0.068). At the end of treatment the three groups were similar. No responder cleared the virus surface marker whose loss signals a cure. No significant side effects were seen.

    Read with care: Small, and patients and doctors knew who was treated. Longer treatment did no better than shorter. FDA points out that the virus test used then was far less sensitive than modern tests, so the same patients might not count as responders today.

    Hepatology · pubmed.ncbi.nlm.nih.gov

  9. Human trial1998

    Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial.

    At the end of treatment, liver blood tests had returned to normal in 37.1% of the combination group, 16.2% of the interferon group and 2.7% of the placebo group (combination versus interferon, P = 0.04).

    Full finding, who was studied, and limits

    Who: 109 patients with chronic hepatitis C, randomised to thymosin alpha-1 plus interferon (35 patients), interferon alone (37) or placebo (37) for 26 weeks.

    At the end of treatment, liver blood tests had returned to normal in 37.1% of the combination group, 16.2% of the interferon group and 2.7% of the placebo group (combination versus interferon, P = 0.04). The virus was undetectable in 37.1% versus 18.9%. A lasting response after treatment stopped was less common: 14.2% versus 8.1%.

    Read with care: Short, and the benefit faded after treatment stopped. FDA notes the paper did not report cure rates as they are measured today. Interferon is no longer a recommended hepatitis C treatment. Modern antiviral pills cure more than 95% of patients, so this result has little bearing on current care.

    Hepatology · pubmed.ncbi.nlm.nih.gov

  10. Review2026

    Thymosin-ɑ1 for people with chronic hepatitis B.

    Compared with control treatments, thymosin alpha-1 may reduce deaths from any cause (risk ratio 0.53, 3 trials, 907 people) and serious adverse events (risk ratio 0.72, 5 trials, 1,056 people), and may have little or no effect on quality of life or liver tissue improvement.

    Full finding, who was studied, and limits

    Who: A Cochrane systematic review and meta-analysis (pooling of results) of 10 randomised trials with 1,349 adults with chronic hepatitis B, run in Bangladesh, China, Italy, Korea, Singapore and Taiwan and published 1991 to 2018. Searches ran to 10 June 2026. Four trials were industry-funded; the review had no dedicated funding.

    Compared with control treatments, thymosin alpha-1 may reduce deaths from any cause (risk ratio 0.53, 3 trials, 907 people) and serious adverse events (risk ratio 0.72, 5 trials, 1,056 people), and may have little or no effect on quality of life or liver tissue improvement. Its effect on hepatitis B-related illness was very uncertain. The authors rated the certainty of evidence as very low for every outcome except serious adverse events (low), and concluded they are not sure whether thymosin alpha-1 reduces deaths or has any other effect.

    Read with care: Very low certainty: most trials had some or high risk of bias, numbers were small, and results varied. Most trials combined thymosin alpha-1 with other drugs such as interferon or antivirals. No new trial since 2018 was found, and 16 studies could not be assessed because of incomplete reporting.

    Cochrane Database of Systematic Reviews · pubmed.ncbi.nlm.nih.gov

  11. Review2025

    Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.

    Pooling all 11 trials, thymosin alpha-1 was linked to fewer deaths at 28 days (odds ratio 0.73, p = 0.003).

    Full finding, who was studied, and limits

    Who: A systematic review and meta-analysis of 11 randomised trials in sepsis (967 patients on thymosin alpha-1, 960 controls), excluding combination treatments, registered with PROSPERO. It also re-analysed patient-level data from two large multicentre trials. Sun Yat-sen University, Guangzhou, China; no conflicts declared.

    Pooling all 11 trials, thymosin alpha-1 was linked to fewer deaths at 28 days (odds ratio 0.73, p = 0.003). But when only high-quality trials (odds ratio 0.82, p = 0.09) or only multicentre trials (odds ratio 0.86, p = 0.20) were included, there was no significant benefit. Possible benefit was seen in patients with cancer (moderate credibility), diabetes or coronary heart disease (low credibility). A further analysis suggested the total number of patients studied is still too small for a firm answer.

    Read with care: The overall benefit disappears in the better-designed trials, which is the more reliable signal. Subgroup findings are hypotheses. It includes the 1,106-patient TESTS trial already on this page, which found no reduction in deaths on its own.

    Frontiers in Cellular and Infection Microbiology · pubmed.ncbi.nlm.nih.gov

  12. Review2024

    Evaluation of Thymosin Alpha-1 (Ta1)-Related Bulk Drug Substances (Ta1 (free base) and Ta1 acetate) for Inclusion on the 503A Bulk Drug Substances List

    FDA concluded there was 'a lack of evidence to support the effectiveness' of thymosin alpha-1 for every one of the 12 uses.

    Full finding, who was studied, and limits

    Who: Not a trial: a review by FDA chemists, toxicologists and physicians of the published human, animal and laboratory studies for 12 proposed uses (hepatitis B, hepatitis C, HIV, COVID-19, vaccine response, melanoma, liver cancer, lung cancer, sepsis, infections after stem cell transplant, chronic lung disease, and chronic fatigue syndrome).

    FDA concluded there was 'a lack of evidence to support the effectiveness' of thymosin alpha-1 for every one of the 12 uses. It described the studies as inconclusive and limited by small size, missing control groups, lack of blinding and outdated comparison treatments. It also found the substance was not well characterised chemically for compounding. FDA proposed not adding it to the pharmacy compounding list. At the meeting the committee voted 17 to 4 against adding each form.

    Read with care: This is a review for one purpose: deciding whether US pharmacies may compound it. It was written in November 2024, before the largest sepsis trial was published. The committee vote is advice, not a final decision. Many of the studies FDA reviewed were old, small or only available as abstracts.

    FDA briefing document for the Pharmacy Compounding Advisory Committee meeting of 4 December 2024 (review dated 15 November 2024) · fda.gov

  13. Review2023

    Thymosin alpha1 use in adult COVID-19 patients: A systematic review and meta-analysis on clinical outcomes.

    Overall, deaths were no lower with thymosin alpha-1 (relative risk 1.03, range 0.60 to 1.75).

    Full finding, who was studied, and limits

    Who: A pooled analysis of 9 studies with 5,352 hospitalised adults with COVID-19 (1,152 given thymosin alpha-1, 4,200 not). Most of the underlying studies looked back at medical records and were not randomised trials.

    Overall, deaths were no lower with thymosin alpha-1 (relative risk 1.03, range 0.60 to 1.75). Subgroups of older and more severely ill patients looked favourable. The authors concluded the results 'do not support the use' of thymosin alpha-1 in hospitalised adults with COVID-19. The individual studies point in different directions. An early report of 76 severe cases in Wuhan found fewer deaths with treatment (11.11% versus 30.00%). A study of 771 critically ill patients at 19 hospitals found no difference once similar patients were compared (51.0% versus 52.9%). A small blinded trial in India (105 patients) reported fewer deaths among severely ill patients on treatment (11.1% versus 38.5%). Another pooled analysis of 8 studies did find lower mortality.

    Read with care: The studies disagreed strongly with one another, most were not randomised, and most date from early 2020, before current treatments and virus variants. FDA's 2024 review counted four pooled analyses, three of which found no reduction in deaths, and judged the evidence insufficient.

    International Immunopharmacology · pubmed.ncbi.nlm.nih.gov

  14. Animal study2004

    Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling.

    Thymosin alpha-1 made dendritic cells mature and produce an immune signalling protein (interleukin-12).

    Full finding, who was studied, and limits

    Who: Dendritic cells (a type of immune cell) in the laboratory, and mice, including mice that had received transplants. Group sizes are not given in the abstract.

    Thymosin alpha-1 made dendritic cells mature and produce an immune signalling protein (interleukin-12). The effect depended on toll-like receptors, the sensors immune cells use to detect infection. In mice it promoted a protective type of immune response to fungus and protected transplanted mice from aspergillosis, a fungal infection.

    Read with care: Cells and mice, not people. FDA's 2024 review notes that most animal studies of thymosin alpha-1 used amounts well above those used in human trials, so it is hard to know how relevant they are.

    Blood · pubmed.ncbi.nlm.nih.gov

Safety findings

  • FDA's 2024 review found that in most clinical studies thymosin alpha-1 was well tolerated, with treatment lasting up to 12 months. The most common side effects were irritation, redness or discomfort where the injection was given. In many studies no side effects were attributed to it. Source: fda.gov
  • In the largest trial (TESTS, 1,089 patients with sepsis analysed), adverse events were recorded in 66.4% of the thymosin alpha-1 group and 67.6% of the placebo group, and serious adverse events in 26.8% and 29.3%. These rates reflect how ill the patients were. The authors reported no unexpected serious adverse events related to the drug. Source: pmc.ncbi.nlm.nih.gov
  • Liver flares in hepatitis B: FDA's review reports that in a trial of 316 Japanese patients, 22 had a temporary worsening of liver blood tests during treatment, and treatment was interrupted in 16. All recovered. The trial's authors noted that such flares also happen in the natural course of hepatitis B. The Indonesian product label warns of the same effect. Source: fda.gov
  • Warnings on product labels abroad, as summarised by FDA: the Italian label says it should not be used in children, is not to be used in pregnancy or while breastfeeding, and calls for caution in people with allergies or autoimmune diseases. The Indonesian label treats it as unsuitable for people whose immune systems are being deliberately suppressed, such as organ transplant patients, unless benefits clearly outweigh risks. Source: fda.gov
5 more safety findings
  • Transplant concern: in a small study of stem cell transplant patients, 1 of 6 who received thymosin alpha-1 with donor immune cells developed a fatal immune reaction that destroyed red blood cells. FDA said it is unclear whether thymosin alpha-1 contributed, and that it is not known whether it could trigger or worsen graft-versus-host disease or graft failure. Source: fda.gov
  • FDA's adverse event database held one applicable US report through 10 June 2024: a man in a hepatitis C trial, also taking interferon, who was admitted to hospital with anxiety and an irregular heartbeat. The interferon could explain it. FDA cautions that few reports does not prove safety, especially for compounded products, which are under-reported. Source: fda.gov
  • Compounded and unregulated versions: FDA's concern is immunogenicity (the body mounting an immune reaction against the peptide), which can be made more likely by clumping of the peptide and by peptide-related impurities, particularly for injections under the skin. The lab reports FDA reviewed for the raw material did not show testing for impurities, clumps, bacterial load or bacterial toxins. FDA's safety-risks web page gives the same concern in brief. Source: fda.gov
  • Animal safety data are thin in the public record. FDA found no published animal studies of short-term toxicity, repeat-dose toxicity, genetic damage, effects on reproduction, or cancer risk. The maker's product document says such studies raised no concerns but does not show the data. FDA concluded the available animal data were too limited to inform safety. Source: fda.gov
  • Use alongside vaccines: FDA said the safety data were insufficient to judge the risks of giving thymosin alpha-1 with US-licensed flu vaccines, and that adding an immune-modifying product to any vaccine could raise safety concerns that need a proper controlled trial. Source: fda.gov

Rules and status

Not approved in the United States. FDA has approved no drug containing thymosin alpha-1, and as of November 2026 it is not on the list of substances that pharmacies may lawfully use for compounding.

The full history, with dates

United States. (1) No approval. FDA's November 2024 review states that neither thymosin alpha-1 nor its acetate salt is a component of an FDA-approved drug. The same document says it holds four US orphan drug designations, and explains that a designation is an incentive for developers of rare-disease drugs, not an approval. (2) Category 2 history. FDA had placed thymosin alpha-1 in Category 2 of its interim compounding policy, the group it says may present significant safety risks. On 18 September 2024 the pharmacy that had nominated it (Wells Pharmacy Network) withdrew the nomination. FDA's safety-risks page, current as of 22 April 2026, now lists it under 'Bulk drug substances nominated but withdrawn'. FDA's stated reason on that page reads: 'Compounded drugs containing thymosin-alpha-1 (Ta1) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. The safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.' Removal because a nomination was withdrawn is not a finding that it is safe. FDA's category list updated 14 May 2026 shows thymosin alpha-1 in none of its three categories. (3) FDA review and advisory vote. FDA chose to evaluate it anyway. Its review dated 15 November 2024 proposed NOT adding either form to the compounding list, citing poor chemical characterisation, insufficient safety information for compounded use, and lack of evidence of effectiveness. On 4 December 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no on adding the free base, and 4 yes and 17 no on adding the acetate salt. The vote is advisory. No proposed or final rule on thymosin alpha-1 was found: a search of the Federal Register on 18 November 2026 returned only the October 2024 meeting notice. (4) July 2026 committee meeting. Thymosin alpha-1 was not on the agenda of the 23 and 24 July 2026 advisory committee meeting, which covered seven other peptides. (5) HHS notice of 30 October 2026. The Federal Register notice (91 FR 68526) announces a draft, non-binding enforcement discretion policy for pharmacy compounding with peptides listed in an appendix. The notice itself names no peptides. Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of 15 November 2026) names exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Thymosin alpha-1 is not among them. Other countries. Thymosin alpha-1 is a licensed medicine in some countries. FDA's review, citing national regulators' websites, reports that Zadaxin is authorised in Italy as an add-on to flu vaccination in people with weakened immune systems, registered in Indonesia and approved in India for chronic hepatitis B, and approved in Hong Kong, and it cites product monographs from Singapore and Mexico. The European Medicines Agency's website also notes the Italian authorisation, and records an orphan designation (not an approval) for liver cancer dated 30 July 2002. The often-repeated figure of 'more than 35 countries' was found only in a review article that cites an earlier review; the maker's 2014 annual report says 'over 30 countries', mainly China and countries in the Pacific Rim, Latin America, Eastern Europe and the Middle East. FDA wrote that it was 'unable to independently verify' the company's claims of approval. No Chinese regulator record was opened for this page; the statement that it is approved in China rests on the company report.

Source: fda.gov (source dated 2026-04-22)

In sport: Not named. Neither the 2026 Prohibited List (in force from 1 January 2026) nor the 2027 List (in force from 1 January 2027) mentions thymosin alpha-1 or thymalfasin. The only thymosin they name is a different molecule: section S2.3 lists 'Thymosin-ß4 and its derivatives e.g. TB-500'. Class S0 (Non-approved substances) covers only 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use'. Thymosin alpha-1 is authorised as a medicine in Italy and approved in some other countries (see the regulatory detail), so S0 does not catch it merely because it is unnamed; the 2027 addition of 'peptides' to the S0 examples does not change that approval test. No WADA statement on thymosin alpha-1 was found either way, and other parts of the List use open-ended wording, so athletes should confirm with their national anti-doping organisation. WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
It is FDA-approved.It is not. FDA states it has approved no drug product containing thymosin alpha-1, and noted a website advertising a compounded product as 'FDA approved'. It does hold orphan drug designations, which are not approvals. Source: fda.gov
It is approved in more than 35 countries, so it must work.The country count comes from company and review-article sources, and FDA said it could not independently verify the company's claims. Where regulators' records were found, the approved uses are narrow, such as hepatitis B treatment or as an add-on to flu vaccination in people with weak immune systems. FDA's own review of the evidence for 12 uses found effectiveness was not shown for any. Source: fda.gov
It boosts the immune system and helps the body fight infections.In the lab and in animals it changes immune cell behaviour, and in patients it has shifted some blood immune markers. But in the largest trial, in 1,106 people with life-threatening infection, it did not reduce deaths, new infections or any other measured outcome. No trial in healthy people for general immune support was found. Source: pubmed.ncbi.nlm.nih.gov
It lowers the risk of dying from sepsis.A 2013 trial of 361 patients reported fewer deaths, on the edge of statistical significance. The larger, double-blind trial that followed found no difference: 23.4% versus 24.1% died within 28 days. Source: pubmed.ncbi.nlm.nih.gov
It treats hepatitis B and hepatitis C.Results were mixed. An unblinded hepatitis B trial found more late responses with treatment; the double-blind placebo-controlled trial did not confirm a benefit. In hepatitis C, a 552-patient trial found no overall difference in cure rates (12.7% versus 10.5%). FDA notes that current antiviral pills cure more than 95% of hepatitis C patients, and warns that using thymosin alpha-1 in place of proven treatment could harm patients. Source: pubmed.ncbi.nlm.nih.gov
It helps people with COVID-19.The evidence conflicts. An early hospital-record study reported fewer deaths, but a larger one found no difference after matching similar patients, and a pooled analysis of 9 studies found no overall effect on deaths. The one US randomised trial (49 patients) found no significant difference in recovery. Source: pubmed.ncbi.nlm.nih.gov
It fights cancer.In a 488-patient melanoma trial, tumours shrank in a few more patients on thymosin alpha-1, but FDA's reading is that neither response rates nor survival were significantly better than in the control group. FDA found the evidence lacking for melanoma, liver cancer and lung cancer. Source: pubmed.ncbi.nlm.nih.gov
It makes vaccines work better.A few small studies found higher flu antibody levels in older men and dialysis patients. None measured whether fewer people became ill. In one study, antibody levels at later time points were higher in the vaccine-only group. FDA concluded there was insufficient evidence that it is an effective vaccine helper. Source: fda.gov
It helps with Lyme disease.FDA reported that it did not identify any clinical studies of thymosin alpha-1 for Lyme disease or for cystic fibrosis, two of the uses put forward when it was nominated for compounding. Source: fda.gov
It has a flawless safety record.FDA quotes that phrase from a 2024 review article and agrees that side effects in trials were mostly mild. But it also lists liver flares in hepatitis B patients, label warnings abroad for pregnancy, children, autoimmune disease and transplant patients, a death in a small transplant study that it could not explain, and unknown risks from impurities and clumping in pharmacy-made versions. Trial safety data come from a regulated product made to a set standard; they do not carry over to unregulated material. Source: fda.gov

What a genuine lab report should show

  • The report should say exactly which substance was tested: thymosin alpha-1 free base or the acetate salt. FDA treats these as different substances, and the lab report submitted with the compounding nomination named one in its title and gave the formula and weight of the other.
  • Identity by mass spectrometry (a method that weighs molecules very precisely) should match the expected molecular weight of about 3108.3 g/mol for the free base (single-isotope mass about 3106.50).
  • The stated sequence should be the 28 amino acids listed on this page, with the acetyl cap on the front end. Without the cap it is a different molecule and would weigh about 42 less.
  • Purity by HPLC (a method that separates a sample into its components), with the largest single impurity and total impurities given as percentages, not just one headline purity figure. FDA noted that the lab reports it found gave a purity result but no impurity limits or results.
  • FDA flagged three tests as missing from the lab reports it reviewed: a bacterial endotoxin test (endotoxins are fever-causing fragments of bacteria), a bioburden test (a count of live microbes), and a check for aggregates (clumped peptide). A fuller report would include them, along with how much peptide is actually in the vial.
  • A lot or batch number that matches the vial, the name of the testing laboratory, and the test date, so the report can be traced to the product in hand.

How to read a lab report

What is not known

  • Whether thymosin alpha-1 helps any particular group of sepsis patients. The TESTS trial hinted at benefit in people aged 60 or over and in people with diabetes, and at possible harm in people under 60, but these were subgroup findings and none has been confirmed in a new trial.
  • The exact hazard ratio for the main TESTS result. PubMed's abstract gives 0.99 (0.77 to 1.27) and the Europe PMC full text gives 0.97 (0.76 to 1.24). A correction was published in May 2025 but could not be opened. The conclusion (no significant difference) is the same either way.
  • How many countries actually license it today, and for what. Only company and review sources give a count ('over 30' or 'more than 35'). FDA could not verify the company's claims, and no Chinese regulator record was opened for this page.
  • Which four conditions the US orphan drug designations cover. FDA's review gives the number only. A review article names melanoma, chronic active hepatitis B, DiGeorge anomaly and liver cancer, but wrongly describes them as approvals; FDA's orphan drug database could not be searched with the tools available.
  • Whether FDA will issue a rule on thymosin alpha-1 after the December 2024 advisory vote against it. None was found.
  • When FDA first placed thymosin alpha-1 in Category 2. The FDA pages opened confirm that it was in Category 2 and was removed after the nomination was withdrawn, but they do not print the date of placement or of removal.
  • Safety of long-term use in healthy people, and whether the body forms antibodies against it. Trials ran for up to 12 months in patients, and FDA found no data settling the immune-reaction question for compounded material.
  • Whether the free base and the acetate salt behave the same way. FDA notes that the published studies often do not say which was used.

Sources

All 44 sources
  1. FDA evaluation of thymosin alpha-1 for the 503A compounding list, dated 15 November 2024 (briefing document for the 4 December 2024 advisory committee meeting). fda.gov
  2. FDA briefing document introduction, 4 December 2024 meeting (FDA's proposals and the withdrawn nomination). fda.gov
  3. FDA summary minutes, Pharmacy Compounding Advisory Committee, 4 December 2024 (vote: 4 yes, 17 no; approved 21 February 2025). fda.gov
  4. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (current as of 22 April 2026). fda.gov
  5. FDA: Bulk drug substances nominated for use in compounding under section 503A, category list (updated 14 May 2026). fda.gov
  6. FDA: Bulk drug substances used in compounding under section 503A (current as of 14 May 2026). fda.gov
  7. Regulations.gov: withdrawal of the thymosin alpha-1 nomination by Wells Pharmacy Network (received 18 September 2024). regulations.gov
  8. Federal Register, 25 October 2024: notice of the 4 December 2024 advisory committee meeting. federalregister.gov
  9. FDA advisory committee calendar: 23-24 July 2026 meeting (thymosin alpha-1 not on the agenda; current as of 6 August 2026). fda.gov
  10. Federal Register, 30 October 2026 (91 FR 68526): HHS notice of a draft enforcement discretion policy for 503A compounding with certain peptides. govinfo.gov
  11. European Medicines Agency: orphan designation EU/3/02/110, thymalfasin for hepatocellular carcinoma (30 July 2002). ema.europa.eu
  12. PubChem CID 16130571: Thymalfasin. pubchem.ncbi.nlm.nih.gov
  13. Goldstein 1977: thymosin alpha1, isolation and sequence analysis of an immunologically active thymic polypeptide. pubmed.ncbi.nlm.nih.gov
  14. Low 1979: isolation, characterization and biological activities of thymosin alpha1 from calf thymus. pubmed.ncbi.nlm.nih.gov
  15. Low and Goldstein 1979: amino acid sequence analysis of thymosin alpha1 (synthetic as active as natural). pubmed.ncbi.nlm.nih.gov
  16. Romani 2004: thymosin alpha 1 activates dendritic cells through toll-like receptor signaling. pubmed.ncbi.nlm.nih.gov
  17. Romani 2006: thymosin alpha1 activates dendritic cell tryptophan catabolism (the braking pathway). pubmed.ncbi.nlm.nih.gov
  18. Mutchnick 1991: thymosin treatment of chronic hepatitis B, placebo-controlled pilot trial (12 patients). pubmed.ncbi.nlm.nih.gov
  19. Chien 1998: thymosin alpha1 in chronic hepatitis B, randomised controlled trial. pubmed.ncbi.nlm.nih.gov
  20. Mutchnick 1999: thymosin alpha1 in chronic hepatitis B, phase III double-blind placebo-controlled trial. pubmed.ncbi.nlm.nih.gov
  21. Iino 2005: thymosin alpha-1 in Japanese patients with chronic hepatitis B (316 patients, two strengths, no placebo). pubmed.ncbi.nlm.nih.gov
  22. Sherman 1998: thymosin alpha1 plus interferon in chronic hepatitis C. pubmed.ncbi.nlm.nih.gov
  23. Ciancio 2012: thymosin alpha-1 added to peginterferon and ribavirin in hepatitis C (552 patients). pubmed.ncbi.nlm.nih.gov
  24. Wu 2013: ETASS trial of thymosin alpha 1 in severe sepsis. pubmed.ncbi.nlm.nih.gov
  25. Wu 2025: TESTS trial of thymosin α1 in sepsis (BMJ). pubmed.ncbi.nlm.nih.gov
  26. TESTS full text (PubMed Central). pmc.ncbi.nlm.nih.gov
  27. TESTS correction notice (BMJ 2025;389:r1098). pubmed.ncbi.nlm.nih.gov
  28. ClinicalTrials.gov NCT02867267: TESTS (completed; sponsor Sun Yat-sen University, collaborator SciClone Pharmaceuticals). clinicaltrials.gov
  29. Shehadeh 2023: pilot trial of thymalfasin in hospitalised COVID-19 patients (United States). pubmed.ncbi.nlm.nih.gov
  30. Shetty 2022: thymosin α1 as add-on treatment in moderate-to-severe COVID-19 (India). pubmed.ncbi.nlm.nih.gov
  31. Liu 2020: thymosin alpha 1 and mortality in severe COVID-19 (76 cases, Wuhan, retrospective). pubmed.ncbi.nlm.nih.gov
  32. Sun 2021: thymosin α1 and mortality of critical COVID-19 patients (771 patients, retrospective). pubmed.ncbi.nlm.nih.gov
  33. Shang 2023: thymosin alpha1 in adult COVID-19 patients, systematic review and meta-analysis. pubmed.ncbi.nlm.nih.gov
  34. Soeroto 2023: thymosin alpha-1 in moderate to critical COVID-19, meta-analysis. pubmed.ncbi.nlm.nih.gov
  35. Gravenstein 1989: thymosin alpha one and influenza antibody response in elderly men. pubmed.ncbi.nlm.nih.gov
  36. Carraro 2012: thymosin-alpha 1 with pandemic H1N1 vaccine in haemodialysis patients (pilot). pubmed.ncbi.nlm.nih.gov
  37. Maio 2010: thymosin alpha 1 with dacarbazine in metastatic melanoma (488 patients). pubmed.ncbi.nlm.nih.gov
  38. Dominari 2020: thymosin alpha 1, a comprehensive review (source of the 'more than 35 countries' figure; review article). pubmed.ncbi.nlm.nih.gov
  39. WADA 2026 Prohibited List (thymosin alpha-1 not named). wada-ama.org
  40. WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
  41. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
  42. Cochrane 2026: thymosin alpha-1 for chronic hepatitis B (10 trials, 1,349 people). pubmed.ncbi.nlm.nih.gov
  43. Gu 2025: systematic review and meta-analysis of thymosin alpha-1 in sepsis (11 trials). pubmed.ncbi.nlm.nih.gov
  44. Li 2026: thymosin alpha-1 in hepatitis B-related acute-on-chronic liver failure (73-patient open-label trial, NCT03082885). pubmed.ncbi.nlm.nih.gov

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.